CRISPR

CRISPR1-trpv6

ID

ZDB-CRISPR-200324-4

Name

CRISPR1-trpv6

Previous Names

None

Target

trpv6 (1)

Sequence

5' - GGGCTCGTTGATGAGCTCCG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
mi604	trpv6
mi605	trpv6
mi606	trpv6

Expression

Gene expression in Wild Types + CRISPR1-trpv6

No data available

Phenotype

Phenotype resulting from CRISPR1-trpv6

No data available

Phenotype of all Fish created by or utilizing CRISPR1-trpv6

Phenotype	Fish	Conditions	Figures
whole organism ab9-mapk labeling decreased amount, abnormal	trpv6^mi604/+; mi602Tg	chemical treatment: U0126	Figure 3 from Xin et al., 2019
NaK ionocyte increased amount, abnormal	trpv6^mi604/+; mi602Tg	chemical treatment: gadolinium trichloride	Figure 2 from Xin et al., 2019
integument ab2-rps6 labeling amount, ameliorated	trpv6^mi604/mi604; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
NaK ionocyte ab2-rps6 labeling amount, ameliorated	trpv6^mi604/mi604; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
integument ab5-akt labeling amount, ameliorated	trpv6^mi604/mi604; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
NaK ionocyte ab2-rps6 labeling increased amount, abnormal	trpv6^mi604/mi604; mi602Tg	control	Figure 3 from Xin et al., 2019
whole organism decreased life span, abnormal	trpv6^mi604/mi604; mi602Tg	control	Figure 1 from Xin et al., 2019
bone element calcium phosphate decreased amount, abnormal	trpv6^mi604/mi604; mi602Tg	control	Figure 1 from Xin et al., 2019
NaK ionocyte ab5-akt labeling increased amount, abnormal	trpv6^mi604/mi604; mi602Tg	control	Figure 3 from Xin et al., 2019
whole organism morphology, abnormal	trpv6^mi604/mi604; mi602Tg	control	Figure 1 supplement 1 from Xin et al., 2019
whole organism ab9-mapk labeling increased amount, abnormal	trpv6^mi604/mi604; mi602Tg	control	Figure 3 from Xin et al., 2019
NaK ionocyte increased amount, abnormal	trpv6^mi604/mi604; mi602Tg	control	Figure 2 , Figure 3 from Xin et al., 2019
NaK ionocyte amount, ameliorated	trpv6^mi604/mi604; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
NaK ionocyte increased amount, abnormal	trpv6^mi604/mi604; mi602Tg	chemical treatment: gadolinium trichloride	Figure 2 from Xin et al., 2019
integument ab5-akt labeling increased distribution, abnormal	trpv6^mi604/mi604; mi602Tg	control	Figure 3 from Xin et al., 2019
whole organism ab9-mapk labeling amount, ameliorated	trpv6^mi604/mi604; mi602Tg	chemical treatment: U0126	Figure 3 from Xin et al., 2019
integument ab2-rps6 labeling increased distribution, abnormal	trpv6^mi604/mi604; mi602Tg	control	Figure 3 from Xin et al., 2019
NaK ionocyte ab5-akt labeling amount, ameliorated	trpv6^mi604/mi604; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
whole organism trpv6 expression increased amount, abnormal	trpv6^mi605/+; mi602Tg	low calcium	Fig. 3 supplemental 1 from Xin et al., 2019
NaK ionocyte increased amount, abnormal	trpv6^mi605/+; mi602Tg	low calcium	Figure 3 from Xin et al., 2019
NaK ionocyte ab2-rps6 labeling amount, ameliorated	trpv6^mi605/mi605; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
integument ab2-rps6 labeling amount, ameliorated	trpv6^mi605/mi605; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
NaK ionocyte amount, ameliorated	trpv6^mi605/mi605; mi602Tg	chemical treatment: wortmannin	Figure 3 from Xin et al., 2019
integument ab5-akt labeling amount, ameliorated	trpv6^mi605/mi605; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
NaK ionocyte ab2-rps6 labeling increased amount, abnormal	trpv6^mi605/mi605; mi602Tg	control	Figure 3 from Xin et al., 2019
NaK ionocyte amount, ameliorated	trpv6^mi605/mi605; mi602Tg	chemical treatment: U0126	Figure 3 from Xin et al., 2019
whole organism decreased life span, abnormal	trpv6^mi605/mi605; mi602Tg	control	Figure 1 from Xin et al., 2019
NaK ionocyte ab5-akt labeling increased amount, abnormal	trpv6^mi605/mi605; mi602Tg	control	Figure 3 from Xin et al., 2019
NaK ionocyte amount, ameliorated	trpv6^mi605/mi605; mi602Tg	chemical treatment: sirolimus	Figure 3 from Xin et al., 2019
NaK ionocyte amount, ameliorated	trpv6^mi605/mi605; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
integument ab5-akt labeling increased distribution, abnormal	trpv6^mi605/mi605; mi602Tg	control	Figure 3 from Xin et al., 2019
NaK ionocyte increased amount, abnormal	trpv6^mi605/mi605; mi602Tg	control	Figure 2 , Figure 3 from Xin et al., 2019
integument ab2-rps6 labeling increased distribution, abnormal	trpv6^mi605/mi605; mi602Tg	control	Figure 3 from Xin et al., 2019
NaK ionocyte ab5-akt labeling amount, ameliorated	trpv6^mi605/mi605; mi602Tg	chemical treatment: BMS-754807	Figure 3 from Xin et al., 2019
NaK ionocyte increased amount, abnormal	trpv6^mi605/mi605; mi602Tg	low calcium	Figure 3 from Xin et al., 2019
NaK ionocyte GCaMP expression decreased amount, abnormal	trpv6^mi606/mi606; mi603Tg/+	control	Figure 4 from Xin et al., 2019
NaK ionocyte GCaMP expression amount, ameliorated	trpv6^mi606/mi606; mi603Tg/+	chemical treatment: ionomycin	Figure 4 from Xin et al., 2019

Citations